The team at Morgans has been busy running the ruler over a number of results this week.
Three popular ASX shares that have come under the spotlight are listed below. Does the broker rate them as buys? Let's find out.
Image source: Getty Images
Netwealth Group Ltd (ASX: NWL)
This investment platform provider delivered a result that was largely in line with expectations.
And while fund inflows have started slowly in FY 2027, Morgans remains positive and has upgraded Netwealth shares to a buy rating with a $27.50 price target. It said:
NWL reported FY26 Revenue +21%; EBITDA +18%; and NPAT +16% on pcp, which was largely in line with MorgF / Consensus expectations. Whilst flows momentum 1Q27 to date has seen a slower start, NWL reaffirmed its FY27 Flows guidance of $18-20bn, with the cadence of flows from MS and other sources expected to step up over the course of the year. We make minor changes to our NPAT forecasts of +1% in FY27-29F, overall, this sees our price target unchanged at A$27.50/sh. We move to a BUY rating.
Sigma Healthcare Ltd (ASX: SIG)
Another ASX share that has been upgraded is Chemist Warehouse owner Sigma Healthcare.
Morgans was pleased with the company's FY 2026 results, which were in line with expectations. In response, the broker has upgraded Sigma Healthcare shares to a buy rating with a $3.19 price target. It explains:
SIG has posted its FY26 result which was in line with our and consensus forecasts. Highlights included EBIT growth of >20%, Australia CW LFL sales were 13.4% (1H 15.0%; 2H: 11.8%), International CW LFL sales of 12.2%. We note the slight moderation in 2H in Australia was driven by a later start to the cold and flu season and cycling a very strong pcp. SIG is targeting double-digit revenue and earnings growth for FY27.
We have reduced our forecast by ~3.5%, which sees our TP reduce to A$3.19 (was A$3.30). The market has marked the shares down 7% post the FY26 results and possible sell down by some of the founders (up to 4.7% of issued capital). We believe the share price fall is overdone and provides us with an opportunity to move our recommendation to BUY (from ACCUMULATE).
Wesfarmers Ltd (ASX: WES)
Bunnings and Kmart owner Wesfarmers delivered a result that was largely in line with expectations.
However, it has started FY 2027 slightly softer than expected. Nevertheless, Morgans has retained its accumulate rating with an improved price target of $85.00. It said:
WES's FY26 result was broadly in line with expectations, although trading in early FY27 was slightly softer, with management also flagging higher capex in FY27. Earnings from Bunnings, Kmart Group and Health were largely in line with expectations, while Officeworks was slightly above our forecasts. WesCEF was modestly weaker than anticipated. Management noted that while consumer demand remains resilient, cost-of-living pressures persist and customers continue to be value-conscious.
We make minimal changes to FY27-29F group EBIT but decrease underlying NPAT by 1-2% due to higher net interest expense. Despite these changes, our target price rises to $85.00 (from $81.10) as we believe the increased investments WES is making in the near term will drive sustainable growth over the long term. This is particularly evident across its retail businesses (Bunnings, Kmart Group, Officeworks and Priceline), where investment should strengthen customer value propositions in a subdued consumer environment and position the divisions to capture stronger growth when economic conditions improve. ACCUMULATE rating maintained.
